Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.
Benzinga Newsdesk 1 year ago
EarningsNews
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.